Ark Therapeutics (AKT)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 0.21 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | -47.7% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Ark Therapeutics Group plc revenues decreased 74% to L1.8M. Net loss before extraordinary items increased from L3.7M to L12.9M. Revenues reflect Revenue from Out-Licensing Deals decrease from L6.5M to L0K. Higher net loss reflects Impairment of Fixed Assets increase from L0K to L1.9M (expense), Impairment of intangible assets increase from L0K to L1.1M (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Ark Therapeutics Group plc is a gene-based medicine company with operations in the United Kingdom and Finland. The principal activity of the Company is the discovery, development and commercialization of products in areas of medicines, with particular focus on vascular disease and cancer. The Company had developed the drug-like small molecule antagonists of VEGF binding to neuropilin-1 receptors (NRP-1) and which in vivo show inhibition of tumour growth with associated anti-cancer activities of inhibiting the development of the tumour blood supply (anti-angiogenic) as well as directly impairing tumour cell growth and motility. It focuses on seeking development and commercialisation partners for its diverse product portfolio. Its biological manufacturing operations are based in Kuopio, Finland, and provide process development and manufacturing for internal programmes and those of third party clients for a variety of stages of therapeutic development.
Directors: Iain Ross (Chmn.) 59, David Venables (CEO) , Russell Banks (CFO) 46, John Martin (CSO) , Edward Bliss (Counsel) , Tim Farries (Other) , Timo Ristola (Other) , Robert Shaw (Other) ,
No. of Employees: 63 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 209,276,676 |
| Free Float | 142.9m (68.3%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Fledgling , FTSE Fledgling XIT, FTSE Techmark Focus , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | , LONDON, W1T 2RJ, United Kingdom |
| Web | http://www.arktherapeutics.com/ |
| Phone | +44 20 73887722 |
| Contact | Nick Plummer (Secy.) |
| Registrar | Capita Registrars Limited (Huddersfield) |
| Auditors | Deloitte LLP |
| Fri 4:41pm | Second Price Monitoring Extn |
| Fri 4:35pm | Price Monitoring Extension |
| 4th Jun | Blocklisting Six Monthly Return |
| 24th May | Second Price Monitoring Extn |
| 24th May | Price Monitoring Extension |
| 17th May | Interim Management Statement |
Recent ↓
